Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2009-011756-22Phase 2Active
Phase 2, open-label, single-arm trial of doxorubicin and capecitabine in breast cancer, sponsored by Azienda Ospedaliero Universitaria di Cagliari. Primary endpoints: Disease-free survival at 3 years, Overall survival at 3 years and 2 more. Started Jun 2009; status: active.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2009-011756-22.